Bio Rad Laboratories Stock Performance
| BIO Stock | USD 278.44 3.23 1.17% |
The firm shows a Beta (market volatility) of 0.82, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bio Rad's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bio Rad is expected to be smaller as well. At this point, Bio Rad Laboratories has a negative expected return of -0.21%. Please make sure to confirm Bio Rad's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Bio Rad Laboratories performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bio Rad Laboratories has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 1.17 | Five Day Return 3.13 | Year To Date Return (8.79) | Ten Year Return 106.8 | All Time Return 10.8 K |
Last Split Factor 2:1 | Last Split Date 2002-03-08 |
1 | The ASX small-cap stock that could double in value in 2026 | 12/15/2025 |
2 | Entry Recap Can Bio Rad Laboratories Inc Class stock surprise with quarterly results - Market Weekly Review Weekly Top Gainers Trade List - moha.gov.vn | 01/12/2026 |
3 | Financial Review Bio-Rad Laboratories Sanuwave Health | 01/29/2026 |
4 | Bio-Rad Q4 Earnings Snapshot | 02/12/2026 |
5 | Bio-Rad Laboratories Q4 Earnings Call Highlights | 02/13/2026 |
6 | Disposition of 3000 shares by Michael Crowley of Bio Rad at 159.32 subject to Rule 16b-3 | 02/19/2026 |
7 | International Markets and Bio-Rad A Deep Dive for Investors | 02/20/2026 |
8 | FDA Approval Deepens Agilent Role In KEYTRUDA Ovarian Cancer Testing | 02/23/2026 |
| Begin Period Cash Flow | 489.8 M | |
| Total Cashflows From Investing Activities | -189.7 M |
Bio Rad Relative Risk vs. Return Landscape
If you would invest 32,150 in Bio Rad Laboratories on November 29, 2025 and sell it today you would lose (4,306) from holding Bio Rad Laboratories or give up 13.39% of portfolio value over 90 days. Bio Rad Laboratories is generating negative expected returns assuming volatility of 2.1819% on return distribution over 90 days investment horizon. In other words, 19% of stocks are less volatile than Bio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Bio Rad Target Price Odds to finish over Current Price
The tendency of Bio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 278.44 | 90 days | 278.44 | about 92.21 |
Based on a normal probability distribution, the odds of Bio Rad to move above the current price in 90 days from now is about 92.21 (This Bio Rad Laboratories probability density function shows the probability of Bio Stock to fall within a particular range of prices over 90 days) .
Bio Rad Price Density |
| Price |
Predictive Modules for Bio Rad
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bio Rad Laboratories. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Bio Rad Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bio Rad is not an exception. The market had few large corrections towards the Bio Rad's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bio Rad Laboratories, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bio Rad within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.25 | |
β | Beta against Dow Jones | 0.82 | |
σ | Overall volatility | 17.55 | |
Ir | Information ratio | -0.12 |
Bio Rad Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bio Rad for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bio Rad Laboratories can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bio Rad Laboratories generated a negative expected return over the last 90 days | |
| Bio Rad Laboratories has a poor financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: FDA Approval Deepens Agilent Role In KEYTRUDA Ovarian Cancer Testing |
Bio Rad Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bio Stock often depends not only on the future outlook of the current and potential Bio Rad's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bio Rad's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27.3 M | |
| Cash And Short Term Investments | 1.5 B |
Bio Rad Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Rad, and Bio Rad fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0167 | ||||
| Profit Margin | 0.29 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 7.24 B | ||||
| Shares Outstanding | 21.92 M | ||||
| Price To Earning | 2.90 X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 2.91 X | ||||
| Revenue | 2.58 B | ||||
| Gross Profit | 1.34 B | ||||
| EBITDA | 475.9 M | ||||
| Net Income | 759.9 M | ||||
| Cash And Equivalents | 529.8 M | ||||
| Cash Per Share | 62.03 X | ||||
| Total Debt | 1.53 B | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 5.50 X | ||||
| Book Value Per Share | 276.16 X | ||||
| Cash Flow From Operations | 532.2 M | ||||
| Earnings Per Share | 27.85 X | ||||
| Market Capitalization | 7.52 B | ||||
| Total Asset | 10.58 B | ||||
| Retained Earnings | 8.18 B | ||||
| Working Capital | 2.39 B | ||||
| Current Asset | 466.61 M | ||||
| Current Liabilities | 208.93 M | ||||
About Bio Rad Performance
By examining Bio Rad's fundamental ratios, stakeholders can obtain critical insights into Bio Rad's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bio Rad is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 218.10 | 150.51 | |
| Return On Tangible Assets | 0.08 | 0.06 | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | 0.07 | 0.06 | |
| Return On Equity | 0.10 | 0.11 |
Things to note about Bio Rad Laboratories performance evaluation
Checking the ongoing alerts about Bio Rad for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Rad Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio Rad Laboratories generated a negative expected return over the last 90 days | |
| Bio Rad Laboratories has a poor financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: FDA Approval Deepens Agilent Role In KEYTRUDA Ovarian Cancer Testing |
- Analyzing Bio Rad's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Rad's stock is overvalued or undervalued compared to its peers.
- Examining Bio Rad's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Rad's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Rad's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Rad's stock. These opinions can provide insight into Bio Rad's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Will Life Sciences Tools & Services sector continue expanding? Could Bio diversify its offerings? Factors like these will boost the valuation of Bio Rad. Projected growth potential of Bio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bio Rad data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.83) | Earnings Share 27.85 | Revenue Per Share | Quarterly Revenue Growth 0.039 | Return On Assets |
Bio Rad Laboratories's market price often diverges from its book value, the accounting figure shown on Bio's balance sheet. Smart investors calculate Bio Rad's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Bio Rad's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bio Rad's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bio Rad should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.